← Leaderboards
Devina Purmessur (walter)
Ohio State University
$1,564,971
Attributed
$2,758,599
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $528.3K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,758,599 · 3
By mechanism
R01$2,019,512 · 1
R21$371,342 · 1
R61$367,745 · 1
Top collaborators
- Natalia Higuita-Castro5 shared
Most similar at Ohio State University
Same institution · by research overlap
- Arunark Kolipaka$3,663,630
- Natalia Higuita-Castro$1,193,629
- Benjamin A. Walter$1,594,828
- Billur Akkaya$1,843,781
- Michael D Lairmore$5,085,750
Others in their field
Other Emerging Leaders on “Operative Surgical Procedures”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,381,339
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Craig Reist · Research Triangle Institute$22,725,934
- Lisa Newman · Research Triangle Institute$22,725,934
Research focus
Operative Surgical ProceduresPain BehaviorMechanicsNucleus PulposusOpioid EpidemicPainInflammatoryLow Back PainFunctional DisorderNerveIn VitroInnovationIntervertebral Disk DegenerationIntervertebral Disc StructureAnimal ModelClinically RelevantIn VivoChronic Low Back PainCellsBlood VesselsInflammationEconomic BurdenDiscogenic PainPathologic
Grant awards (7)
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$481,575
R01 · FY2025 · AR · contact PI
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$492,331
R01 · FY2024 · AR · contact PI
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$517,259
R01 · FY2023 · AR · contact PI
Novel non-viral reprogramming strategies to treat Discogenic back pain via engineered extracellular vesicles$528,347
R01 · FY2022 · AR · contact PI
Immune-modulation in canine models of painful intervertebral disc degeneration$199,742
R21 · FY2021 · AR · contact PI
Immune-modulation in canine models of painful intervertebral disc degeneration$171,600
R21 · FY2020 · AR · contact PI
Non-viral Reprogramming of Intervertebral Disc Cells for the treatment of Discogenic back pain$367,745
R61 · FY2019 · AR · contact PI